Background The KEYNOTE-966 study demonstrated that pembrolizumab combined with chemotherapy is more effective than chemotherapy alone as first-line treatment for patients with advanced biliary tract ...

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa ...

The bispecific antibody tovecimig (formerly CTX-009) elicited responses among patients with biliary tract cancer receiving treatment in the second-line setting, according to recently announced study ...

In the treatment of newly diagnosed biliary tract cancer, the current standard of care involves chemotherapy in combination with immunotherapy, utilizing agents such as Imfinzi (durvalumab) or ...

Biliary tract cancers (BTCs) are a heterogeneous group of malignancies including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder carcinoma (GBC). Patients ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with HER2 ...

Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug for the treatment of a type of biliary tract cancer, the company said on ...

The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer. Zanidatamab-hrii (Ziihera ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of ...

Oncology/Hematology > Other Cancers FDA Approves Zanidatamab for Biliary Tract Cancer — New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease by Mike ...

More than a week ahead of its priority PDUFA date, the U.S. FDA has greenlit the first dual HER2-targeted bispecific antibody specifically for previously treated, unresectable or metastatic ...